Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc > Progression free survival rate
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(51)
•••
Comment by Qwerty54321on Jun 01, 2024 10:55pm
103 Views
Post# 36067984

RE:Progression free survival rate

RE:Progression free survival rate

I get ur point but you have to look at what other lung cancer drugs are capable of doing. It's the limited affects of other drugs that make this one look good (in lung cancer).


scarlet1967 wrote:

 

 

This bispecific antibody stops immunosuppression and blood supply process both responsible for progression of the cancer. The drug is now approved in combo therapy for cancer in China!

Different MOA but one could not ignore long term efficacy of cancer drugs and their place in the market as a stand alone drug or in combination with chemotherapy.

I thought it was interesting to bring this up as sudocetaxel zendusortide managed to stabilize the disease for long time.

https://ca.finance.yahoo.com/news/summit-shares-soar-lung-cancer-195343904.html

https://ca.finance.yahoo.com/news/ivonescimab-combination-chemotherapy-approved-china-230000301.html


 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities